Global collaborations boost dataset powering AI diagnostics for cancer, cardiovascular and autoimmune diseases

Biostate AI has launched new collaborations in the US, China, and India to expand access to its RNA sequencing-based precision medicine platform, following a $12 million Series A round.

The US-based biotech has formed a joint venture in China and multi-year research partnerships in Boston and Bengaluru, significantly expanding the global dataset powering its AI-driven diagnostics.

Founded by former professors and entrepreneurs David Zhang and Ashwin Gopinath, Biostate AI builds machine learning models using RNA sequencing — a snapshot of real-time gene activity — to guide treatment decisions, inform clinical trial design and improve patient outcomes.

The company has established a subsidiary in India, Bayosthiti, focused on developing diagnostics tailored to the Indian population in collaboration with hospital networks and cancer institutes. In China, Biostate AI has partnered with Kindstar Global Gene Technology to launch a joint venture targeting high-prevalence diseases including autoimmune disorders, oral cancer, diabetes, lymphoma and post-transplant care.

This expansion also builds on a US-based collaboration with Mass General Brigham to develop a diagnostic model to improve melanoma immunotherapy, with plans to scale the approach to other tumor types.

“Our technologies have been validated through collaborations with over 100 academic and biotech partners in the US, and now we’re applying these proven capabilities to India’s unique healthcare setting,” said Ashwin Gopinath, co-founder and CTO of Biostate AI.

“Our confluence of advanced AI models and wet chemistry innovations gives us both a data advantage and the ability to generate insights that were previously impossible.”

Cancer remains one of India’s fastest-growing health challenges, with more than 1.4 million new diagnoses annually. Many Indian patients rely on diagnostics trained on Western datasets, which may not reflect population-specific biology. Biostate AI aims to close that gap by generating localized RNA-based insights.

“We’re thrilled to partner with Kindstar Global. As a leading specialty testing provider in China, their national clinical network of over 3,000 hospitals and deep market resources make them an ideal partner,” said David Zhang, co-founder and CEO of Biostate AI.

In its US collaboration, Biostate AI is working with Mass General Brigham’s melanoma and sarcoma teams to improve patient stratification for immune checkpoint inhibitors — therapies that can be transformative but often carry severe side effects.

“Our group has assembled thousands of paired tumour and blood specimens linked to detailed longitudinal outcomes,” said Genevieve Boland, section head of melanoma/sarcoma surgery at Massachusetts General Hospital.

“This collaboration allows us to leverage AI in new ways to unlock that data, which can better inform patient care in the future.”

Biostate AI and Mass General Brigham aim to build a generalizable diagnostic model trained on the hospital’s extensive biobank. While the initial focus is melanoma, the platform is tumor-agnostic and could apply to other cancers treated with immune checkpoint inhibitors.

The company also emphasizes cost-effectiveness and access as central goals. By generating population-specific data and lowering the cost of biomarker development, Biostate AI hopes to improve global health outcomes and reduce reliance on one-size-fits-all diagnostics.